Return to homepagePandemic Pact

Immunosenescence as a risk factor for SARS-CoV-2 infection

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_00314

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)

  • Principal Investigator

    David Otaegui, Alvaro Prada

  • Research Location

    Spain

  • Lead Research Institution

    ASOCIACION INSTITUTO BIODONOSTIA

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older), Older adults (65 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

In this project we intend to make a rapid approach to the status of lymphocyte populations and the inflammation process in positive COVID19 patients with and without symptoms compared to negative COVID19 patients. With the hypothesis that immunosenescence is playing a role in the susceptibility to being infected, the studies will be carried out in different age ranges (30-40 / 40-50 / 50-60 / older than 60). In the case of COVID19 positive patients, the immunosenescence and inflammation profiles at the time of diagnosis will be correlated with the clinical variables for monitoring the disease in search of prognostic markers of evolution.